Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Stress-activated protein kinase jnk-1 | 0.0518 | 0.5105 | 0.4547 |
Schistosoma mansoni | serine/threonine protein kinase | 0.032 | 0.3041 | 0.3041 |
Schistosoma mansoni | kinase | 0.017 | 0.1479 | 0.1479 |
Loa Loa (eye worm) | hypothetical protein | 0.0969 | 0.9804 | 0.9971 |
Brugia malayi | Serine/threonine-protein kinase F42G10.2 | 0.017 | 0.1479 | 0.0362 |
Loa Loa (eye worm) | CMGC/MAPK/JNK protein kinase | 0.0518 | 0.5105 | 0.4547 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0971 | 0.9829 | 1 |
Schistosoma mansoni | protein kinase | 0.014 | 0.1166 | 0.1166 |
Brugia malayi | Protein kinase domain containing protein | 0.0971 | 0.9829 | 1 |
Echinococcus multilocularis | mitogen activated protein kinase kinase kinase | 0.0329 | 0.3134 | 0.2272 |
Onchocerca volvulus | Kinase homolog | 0.017 | 0.1479 | 0.5 |
Loa Loa (eye worm) | TKL/MLK/LZK protein kinase | 0.0971 | 0.9829 | 1 |
Echinococcus granulosus | c-Jun N-terminal kinases | 0.0518 | 0.5105 | 0.4547 |
Loa Loa (eye worm) | hypothetical protein | 0.0969 | 0.9804 | 0.9971 |
Echinococcus granulosus | mitogen activated protein kinase kinase kinase | 0.0971 | 0.9829 | 1 |
Loa Loa (eye worm) | STE/STE7/MEK4 protein kinase | 0.017 | 0.1479 | 0.0362 |
Echinococcus granulosus | dual specificity mitogen activated protein | 0.017 | 0.1479 | 0.0362 |
Echinococcus multilocularis | dual specificity mitogen activated protein | 0.017 | 0.1479 | 0.0362 |
Echinococcus multilocularis | c Jun NH2 terminal kinase | 0.0518 | 0.5105 | 0.4547 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0518 | 0.5105 | 0.5105 |
Echinococcus granulosus | mitogen-activated protein kinase kinase kinase 9 | 0.0329 | 0.3134 | 0.2272 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.